SELLAS GPS Trial Cuts Death Risk 41% as Company Launches $150M Offer
A TradingView analysis says SELLAS's GPS vaccine delivered 24.0 months of median survival in Phase 3, but a $150 million offering, 2026 patent expiries and Shanghai-based supply test the bet.
By Daniel Okafor
3 min read

What's News
- GPS delivered median survival of 24.0 months versus 14.7 months on best available treatment in the Phase 3 REGAL trial.
- The REGAL trial reported a 41% lower risk of death and a p-value of 0.035.
- SELLAS shares rose 156% in one session before the company launched a $150 million share offering.
- Several original U.S. GPS peptide patents expire from 2026 onward; Memorial Sloan Kettering owns most underlying science, UDIS_View says.
- SLS009 comes from Shanghai-based GenFleet, which manufactures every dose.
By Daniel Okafor
Median survival reached 24.0 months with SELLAS Life Sciences Group, Inc.’s (Nasdaq: SLS) galinpepimut-S (GPS) vaccine in the pivotal Phase 3 REGAL trial, according to a TradingView analysis by UDIS_View.
UDIS_View reported that patients with acute myeloid leukemia in second remission lived 24.0 months on GPS, compared with 14.7 months on best available treatment. The analysis put the benefit at a 41% lower risk of death. UDIS_View called the result “what few small biotechs ever achieve.”
SELLAS shares rose 156% in one session, UDIS_View said. Within hours, the company launched a $150 million share offering. The analysis made dilution a central financing question for investors.
What did the Phase 3 REGAL trial show?
GPS uses modified peptides that train the immune system to attack WT1, a protein many leukemias overproduce, UDIS_View explained. Earlier WT1 vaccines failed against bulky solid tumors, according to the analysis. SELLAS therefore targeted patients with only residual disease after chemotherapy. The analysis said no approved maintenance therapy exists in this setting.
The design narrowed the clinical contest. UDIS_View said earlier attempts had failed against bulky tumors. GPS instead tested a post-chemotherapy population with an unmet need. The result supports that mechanism without settling every question about durability.
Yet UDIS_View said key statistics remain unpublished. The missing materials include the confidence interval and survival curves. Without that interval, investors cannot see the precision of the 41% risk reduction.
The reported p-value of 0.035 leaves little margin, according to UDIS_View. The trial also ran open-label. Full data must determine whether the survival benefit holds. Those missing outputs prevent investors from sizing the result with the same confidence as the headline.
Can GPS retain protection after approval?
Several original U.S. patents covering GPS peptides expire from 2026 onward, UDIS_View said. Memorial Sloan Kettering owns most of the underlying science, according to the analysis. UDIS_View therefore concluded that FDA exclusivity, not patents, would form GPS’s real moat after approval.
The source’s conclusion shifts the post-approval moat toward regulatory exclusivity. Patent protection would begin eroding from 2026, while the FDA’s 2027 response determines whether a regulatory shield becomes available.
For investors, a clinical win and a durable exclusivity period are not the same outcome. UDIS_View put intellectual property timing alongside FDA review and full data as a central part of the post-REGAL debate. The patent clock can therefore matter as much as the efficacy clock.
How concentrated is SLS009’s supply chain?
SELLAS’s second drug, SLS009, comes from Shanghai-based GenFleet, according to UDIS_View. GenFleet also manufactures every dose. The arrangement combines drug origin and production in one Shanghai-based counterparty.
Clinical geography does not determine manufacturing geography. Even with trials running in the United States and Europe, SELLAS still relies on GenFleet for every dose. With the BIOSECURE Act already law, UDIS_View said that dependence carries growing geopolitical weight.
What will investors watch in 2027?
UDIS_View said: “For investors, the trial has shifted the debate rather than settled it.” The analysis left three questions:
- How the FDA responds in 2027.
- Whether full survival data confirm the reported benefit.
- How much dilution the $150 million share offering creates.
The analysis provided no share count or offer price. It therefore could not calculate the final dilution. The confidence interval and survival curves also remain unavailable for investor scrutiny.
UDIS_View said SELLAS had crossed its clinical hurdle. The company still faces regulatory, commercial and geopolitical hurdles, according to the analysis.
For investors, the next dated test is the FDA’s 2027 response. Approval would put regulatory exclusivity at the center of GPS’s protection. Full data, offering dilution and GenFleet’s manufacturing role remain unresolved.
Source: tradingview.com
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,360 articles